wiraxon

WiraXon (Shanghai) Medical Device Co., Ltd. was established in July 2025, with Ning Chong as the chairman of the board. The company is located in the Pudong New Area of Shanghai. As an enterprise specializing in the medical device field, its main business covers the production of Class II medical devices and the production and operation of Class III medical devices. The company is based in the healthcare industry, focusing on the research, development, and manufacturing of medical devices, providing professional products and services to the medical field. WiraXon has demonstrated unique technological advantages in the brain-computer interface field, with its globally pioneering minimally invasive brain-spinal interface technology receiving Breakthrough Therapy Designation from the U.S. FDA, laying the foundation for product internationalization. The company has filled the technical gap in the treatment of spinal cord injuries through neural pathway repair technology, and its clinical transformation capabilities have been strengthened under the collaborative development of the brain-computer interface industry. The science and technology innovation policies in Shanghai provide a favorable R&D environment for WiraXon, enabling it to focus on core technology breakthroughs. Recently, WiraXon invested in building a research and production headquarters in the Waigaoqiao New Exhibition City Park, concentrating on the industrialization of implantable brain-spinal nerve stimulation systems, with an investment scale of approximately 100 million yuan. The brain-spinal interface technology developed in collaboration with Fudan University received Breakthrough Therapy Designation from the U.S. FDA, becoming the first domestic medical device of its kind. This technology has already helped paralyzed patients regain motor function in clinical trials.